🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 26/10/2021 | 185,02 | 186,58 | 183,95 | 184,07 | -0,50% | 1,42% | 1.003.400 |
| 25/10/2021 | 183,52 | 186,14 | 182,51 | 184,99 | +0,80% | 1,98% | 982.600 |
| 22/10/2021 | 186,77 | 187,15 | 182,88 | 183,52 | -1,91% | 2,29% | 1.945.200 |
| 21/10/2021 | 185,54 | 187,20 | 184,34 | 187,09 | +0,86% | 1,54% | 1.629.100 |
| 20/10/2021 | 185,99 | 187,88 | 185,08 | 185,49 | +0,04% | 1,51% | 1.623.500 |
| 19/10/2021 | 182,06 | 185,60 | 181,11 | 185,41 | +2,55% | 2,47% | 2.011.200 |
| 18/10/2021 | 182,50 | 182,70 | 177,71 | 180,80 | -0,53% | 2,73% | 2.335.900 |
| 15/10/2021 | 182,48 | 183,15 | 181,00 | 181,77 | -0,07% | 1,18% | 1.409.200 |
| 14/10/2021 | 182,14 | 184,19 | 181,33 | 181,90 | +0,31% | 1,57% | 1.913.400 |
| 13/10/2021 | 180,22 | 182,50 | 180,22 | 181,34 | +0,63% | 1,27% | 1.088.900 |
| 12/10/2021 | 181,51 | 181,51 | 179,31 | 180,21 | +0,35% | 1,21% | 1.425.000 |
| 11/10/2021 | 179,23 | 181,02 | 178,21 | 179,58 | +0,36% | 1,57% | 1.533.000 |
| 08/10/2021 | 180,27 | 181,02 | 178,58 | 178,94 | -0,60% | 1,35% | 1.157.800 |
| 07/10/2021 | 180,91 | 182,00 | 179,72 | 180,02 | -0,49% | 1,26% | 1.287.300 |
| 06/10/2021 | 177,01 | 182,58 | 176,36 | 180,91 | +2,20% | 3,51% | 1.723.000 |
| 05/10/2021 | 177,50 | 179,40 | 176,92 | 177,01 | -0,22% | 1,40% | 1.802.600 |
| 04/10/2021 | 179,00 | 181,00 | 177,04 | 177,40 | -1,64% | 2,21% | 1.647.900 |
| 01/10/2021 | 180,16 | 181,15 | 178,35 | 180,35 | -0,57% | 1,55% | 1.355.800 |
| 30/09/2021 | 182,48 | 184,21 | 181,37 | 181,39 | -0,46% | 1,56% | 1.322.100 |
| 29/09/2021 | 182,17 | 184,25 | 181,96 | 182,22 | +0,34% | 1,26% | 1.100.800 |
| 28/09/2021 | 182,40 | 183,32 | 180,02 | 181,60 | -0,99% | 1,81% | 1.589.100 |
| 27/09/2021 | 183,20 | 184,05 | 181,45 | 183,41 | -0,11% | 1,42% | 1.469.900 |
| 24/09/2021 | 185,30 | 185,30 | 181,98 | 183,61 | -0,80% | 1,79% | 1.159.800 |
| 23/09/2021 | 184,62 | 186,50 | 184,50 | 185,09 | +0,44% | 1,08% | 1.076.300 |
| 22/09/2021 | 186,12 | 186,44 | 182,60 | 184,27 | -0,82% | 2,06% | 1.376.000 |
| 21/09/2021 | 186,17 | 187,49 | 185,11 | 185,80 | +0,07% | 1,28% | 913.500 |
| 20/09/2021 | 186,89 | 188,89 | 185,07 | 185,67 | -1,40% | 2,04% | 1.874.400 |
| 17/09/2021 | 186,24 | 188,54 | 184,78 | 188,30 | +0,64% | 2,02% | 2.214.200 |
| 16/09/2021 | 188,85 | 189,54 | 185,44 | 187,10 | -0,93% | 2,17% | 1.548.200 |
| 15/09/2021 | 188,47 | 190,60 | 188,42 | 188,86 | +0,24% | 1,16% | 1.599.100 |